Market revenue in 2023 | USD 12.2 million |
Market revenue in 2030 | USD 20.8 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.25% in 2023. Horizon Databook has segmented the Brazil cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil is currently the first Latin American country to authorize gene therapy product marketing. More specifically, Novartis' gene therapy drugs Luxturna and Zolgensma were given marketing approval by the Brazilian Health Regulatory Agency (ANVISA) in September 2020.
Luxturna received its marketing authorization on August 6, 2020, as stated in the Brazilian Federal Register. A few days later, on 17 August 2020, Zolgensma received its marketing authorization. Both products had been approved by the Brazilian Technical Commission of Biosafety (CTNBio), which is responsible for assessing the biosafety of Genetically Modified Organisms (GMOs) in Brazil, prior to ANVISA's final opinions.
Moreover, bioanalytical testing services for cell and gene therapy are anticipated to grow in the country due to the strong growth and innovation in the biologics industry as well as the expanding biopharmaceutical market.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into Brazil cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account